| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $262.5M | +17.1% | +73.0% |
| SG&A Expense | $52.8M | +30.0% | +120.2% |
| Operating Income | -$315.3M | -19.1% | -79.4% |
| Pre-tax Income | -$305.2M | -23.2% | -95.3% |
| Net Income | -$305.2M | -23.2% | -95.3% |
| EPS (Basic) | -$1.61 | -22.9% | -71.3% |
| EPS (Diluted) | -$1.61 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $217.4M | -46.0% | +8.0% |
| Short-term Investments | $1.71B | -1.2% | +27.1% |
| Current Assets | $1.98B | -9.1% | +25.2% |
| Total Assets | $2.25B | -7.3% | +27.7% |
| Current Liabilities | $245.6M | +33.1% | +121.6% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$623.5M | — | — |
| Capital Expenditures | $14.1M | — | — |
| Investing Cash Flow | $43.2M | — | — |
| Financing Cash Flow | $255.9M | — | — |
| Free Cash Flow | -$637.6M | — | — |
| -22.9% |
| -71.3% |
| $655.0M |
| +16.1% |
| +233.0% |
| Stockholders' Equity | $1.60B | -14.4% | +2.0% |